- IN₹243.74bn
- IN₹216.78bn
- IN₹22.81bn
- 85
- 13
- 94
- 74
Annual balance sheet for Pfizer, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,025 | 16,204 | 18,464 | 20,341 | 27,885 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,247 | 2,481 | 1,930 | 2,399 | 2,147 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19,247 | 23,614 | 24,933 | 27,378 | 35,129 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,951 | 2,201 | 1,855 | 1,514 | 1,795 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 32,659 | 39,005 | 40,007 | 42,288 | 49,111 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7,743 | 8,529 | 6,574 | 5,466 | 5,695 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 8,729 | 10,361 | 7,934 | 6,332 | 6,937 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 23,930 | 28,644 | 32,073 | 35,955 | 42,174 |
Total Liabilities & Shareholders' Equity | 32,659 | 39,005 | 40,007 | 42,288 | 49,111 |
Total Common Shares Outstanding |